Area of research
Oncology · Dermatology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Cutaneous lymphoproliferative disorders research, and Allergic Rhinitis and Sensitization.
Discordance, accuracy and reproducibility study of pathologists’ diagnosis of melanoma and melanocytic tumors
Re-resection of brain metastases – outcomes of an institutional cohort study and literature review
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg
Infliximab is a safe and effective treatment in steroid-refractory immune-related hepatitis
Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature
Body Composition and Inflammation as Emerging Sex-Specific Prognostic Factors in Patients with Advanced Cutaneous Melanoma Undergoing Immune Checkpoint-Inhibition Therapy: A Prospective Pilot Study
Real‐world management of patients with complete response under immune‐checkpoint inhibition for advanced melanoma
Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics
Prospective multicenter study using artificial intelligence to improve dermoscopic melanoma diagnosis in patient care
Patients’ and dermatologists’ preferences in artificial intelligence–driven skin cancer diagnostics: A prospective multicentric survey study
S2k guideline basal cell carcinoma of the skin (update 2023)
Real-World Pattern-of-Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members
Using multiple real-world dermoscopic photographs of one lesion improves melanoma classification via deep learning
S2k‐Leitlinie Basalzellkarzinom der Haut (Aktualisierung 2023)
Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis
Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial
Explainable artificial intelligence in skin cancer recognition: A systematic review
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021
Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
Real‐world outcomes using <scp>PD</scp>‐1 antibodies and <scp>BRAF</scp> + <scp>MEK</scp> inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma